Teva Gets Investment From Royalty On Olanzapine LAI
Follows Successful Launch Of Uzedy LAI Risperidone In The US Earlier This Year
Executive Summary
Teva has announced a new investment from Royalty Pharma in its long-acting injectable formulation of olanzapine that is being developed for the US market with partner MedinCell.
You may also be interested in...
Teva Delivers First US Forteo Equivalent
Teva has celebrated a US nod for its generic version of Forteo, the first substitutable teriparatide rival to be approved by the US Food and Drug Administration.
Teva Prepares To Launch LAI Risperidone After US Approval
Teva has indicated an imminent launch after gaining a long-awaited FDA approval for the Uzedy long-acting injectable risperidone 505(b)(2) hybrid product on which the firm has partnered with MedinCell. Pricing information has also been revealed.
Teva-MedinCell Alliance Heats Up With Second Phase III Trial Underway
Teva’s partnership with MedinCell for long-acting injectable products, first penned a decade ago, is beginning to gather steam, as another candidate entered the clinic ahead of a potential first approval in the coming months.